Hematocrit, Nutrition, and Fasting: What Raises or Lowers Your Reading

What Hematocrit Measures and Why It Matters

Hematocrit is expressed as a percentage and is calculated by spinning whole blood in a centrifuge until red cells pack into a pellet. That packed-cell volume divided by total blood volume gives you the number. Because it captures the proportion rather than the absolute count, it is sensitive to two independent variables: the actual red cell mass and the plasma volume.

Understanding which of those two variables is driving a high or low reading changes management entirely. A hematocrit of 52% in a dehydrated man after a long run means something different from a 52% reading in a man on weekly testosterone cypionate injections who is fully hydrated.

The Difference Between True Polycythemia and Relative Polycythemia

True (absolute) polycythemia occurs when red cell mass is genuinely elevated, as seen in polycythemia vera or TRT-driven erythrocytosis. Relative (spurious) polycythemia occurs when plasma volume contracts, concentrating existing red cells without any actual increase in erythropoiesis. Dehydration is the most common cause of relative polycythemia.

Clinicians in one 2017 review noted that distinguishing the two requires either a repeat test after rehydration or a direct red cell mass measurement using chromium-51-labeled erythrocytes, though the latter is rarely done outside hematology.

Why the Distinction Is Clinically Significant

Treating relative polycythemia with phlebotomy is unnecessary and potentially harmful; correcting dehydration resolves it within 24 hours. Treating true erythrocytosis from TRT, on the other hand, may require dose reduction, a switch from intramuscular to transdermal delivery, or therapeutic phlebotomy depending on the clinical picture. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends withholding or reducing testosterone when hematocrit exceeds 54%.

Hydration: The Fastest-Moving Variable

Plasma volume changes faster than red cell mass. Within 60 minutes of significant fluid loss, hematocrit can rise measurably, and within 60 minutes of aggressive oral rehydration, it can fall.

How Much Does Dehydration Raise Hematocrit?

A controlled study published in the Journal of Applied Physiology demonstrated that a 2% loss of body weight through sweating elevated hematocrit by approximately 2 to 4 percentage points in healthy adults. The same paper confirmed that this effect was fully reversible after oral rehydration.

At a 4% body-weight deficit, the rise can reach 5 to 6 percentage points. A man whose well-hydrated baseline sits at 47% could display a reading of 52 to 53% on a hot day after intense exercise, which is a clinically important distinction to make before recommending intervention.

Practical Implications for Lab Timing

Blood draws for hematocrit should be taken in the morning after at least 8 hours of overnight rest, in a euhydrated (adequately hydrated) state. Patients should drink approximately 250 to 500 mL of water 30 to 60 minutes before the draw. Strenuous exercise the day before can artifactually suppress hematocrit if there is transient plasma expansion (the "sports anemia" effect), or raise it if sweat losses were large and incompletely replaced.

Fasting: What the Evidence Shows

Short-term fasting has a modest and inconsistent effect on hematocrit compared with hydration. The key variable is whether fasting is accompanied by reduced fluid intake.

Fasts Under 12 Hours

A 12-hour overnight fast in a euhydrated individual produces no clinically meaningful change in hematocrit. The National Health and Nutrition Examination Survey (NHANES) reference intervals for hematocrit are derived from fasting specimens, and the Endocrine Society recommends fasting blood draws primarily for glucose and lipids rather than for complete blood count parameters.

Extended Fasting (24 to 72 Hours)

Prolonged fasting, particularly in protocols such as 48-hour water fasts or extended protein-restricted periods, can cause a paradoxical fall in hematocrit if significant lean-mass catabolism releases intracellular water and expands plasma volume. Conversely, if fluid restriction accompanies the fast, hematocrit rises from relative polycythemia. Neither effect is large in magnitude: observed changes in controlled studies rarely exceed 2 percentage points in both directions.

A 2019 study in Frontiers in Physiology examining a 7-day caloric restriction protocol found no statistically significant change in hematocrit (mean delta: 0.4%, P<0.05 threshold not reached) when subjects maintained normal water intake throughout.

Intermittent Fasting and TRF Protocols

Time-restricted feeding (TRF) windows of 16:8 or 18:6 do not appear to affect hematocrit in healthy adults based on current data. The primary metabolic benefits of these protocols (insulin sensitivity, weight loss) are mediated through pathways unrelated to erythropoiesis. Patients on TRT following TRF protocols should not expect their hematocrit to improve or worsen from the fasting schedule itself.

Iron Intake: The Most Powerful Nutritional Lever

Iron is the rate-limiting nutrient for hemoglobin synthesis. Because hematocrit tracks hemoglobin closely (hematocrit ≈ hemoglobin × 3 by convention), iron status is the single dietary variable with the greatest direct effect on hematocrit.

Iron Deficiency and Low Hematocrit

Iron-deficiency anemia affects approximately 1.6 billion people worldwide, according to the World Health Organization. In iron-deficient states, hematocrit falls below 36% in adult females and below 39% in adult males. Dietary iron absorption from heme sources (red meat, organ meats, shellfish) averages 15 to 35%, while non-heme sources (legumes, leafy greens, fortified cereals) average 2 to 10%.

A 2020 Cochrane review of iron supplementation in iron-deficient non-pregnant adults confirmed that oral iron supplementation raised hemoglobin by a mean of 7.8 g/L and hematocrit by approximately 2 to 3% over 8 to 12 weeks, with ferrous sulfate at 60 to 120 mg elemental iron daily being the most studied regimen.

Iron Overload and Elevated Hematocrit

High dietary iron or supplementation without confirmed deficiency does not meaningfully raise hematocrit in iron-replete individuals, because intestinal absorption is tightly regulated by hepcidin. Hemochromatosis, a genetic disorder causing dysregulated iron absorption, is the exception: untreated hereditary hemochromatosis can raise hematocrit to 54 to 58% alongside ferritin values exceeding 1,000 ng/mL. The American Association for the Study of Liver Diseases guideline on hemochromatosis recommends therapeutic phlebotomy to maintain hematocrit below 39% during active depletion.

Vitamin C and Iron Absorption

Concurrent intake of 100 to 200 mg vitamin C with non-heme iron sources increases non-heme absorption by 67 to 190% depending on the meal's inhibitor content. For patients with borderline-low hematocrit from dietary iron insufficiency, pairing iron-rich plant foods with a vitamin C source is a practical and low-risk intervention.

Folate and Vitamin B12: The Overlooked Pair

Iron deficiency gets most of the attention, but folate and B12 deficiencies cause macrocytic anemia with a characteristically low hematocrit, often in the range of 28 to 36%.

Folate Deficiency

Folate is required for DNA synthesis in rapidly dividing erythroid precursors. Without adequate folate, cells grow large but fail to divide properly, producing fewer, larger red cells (macrocytosis) and a falling hematocrit. The recommended dietary allowance (RDA) for folate is 400 mcg DFE/day for adults, rising to 600 mcg DFE/day in pregnancy. Alcohol excess is a major driver of functional folate deficiency because alcohol impairs intestinal absorption and hepatic folate storage.

Vitamin B12 Deficiency

B12 deficiency produces a near-identical blood picture to folate deficiency. The distinction matters because treating B12 deficiency with folate alone can mask neurological deterioration. Strict vegans, patients on metformin, and those over age 65 with reduced gastric acid secretion are at highest risk. A 2012 NHANES analysis showed that 3.6% of adults aged 40 to 59 and 6.0% of adults 70 and older had B12 deficiency (serum B12 <148 pmol/L), with corresponding mean hematocrit values in the anemic range.

Testosterone Replacement Therapy and Hematocrit

TRT is the most clinically significant pharmacological driver of elevated hematocrit in a telehealth setting. Testosterone stimulates erythropoietin (EPO) production in the kidneys and directly suppresses hepcidin, leading to increased intestinal iron absorption and accelerated erythropoiesis.

Magnitude and Timeline of the Effect

In the Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in 788 men aged 65 and older with low testosterone, hematocrit rose by a mean of 3.4 percentage points at 12 months in the testosterone group versus 0.8 percentage points in placebo. The rise was dose-dependent: intramuscular formulations producing higher peak testosterone levels generated larger hematocrit increases than transdermal gels.

Approximately 5.7% of men in the TTrials testosterone arm developed hematocrit above 54%, meeting the Endocrine Society's definition of erythrocytosis requiring intervention.

Delivery Route Matters

Peak testosterone levels after intramuscular injection of testosterone cypionate or enanthate (typically 200 mg every 2 weeks) are substantially higher than those achieved with daily transdermal gel or weekly testosterone undecanoate injections. Because erythropoietic drive correlates with peak testosterone concentration rather than average levels, switching from intramuscular to transdermal delivery frequently reduces hematocrit by 2 to 4 percentage points without changing total testosterone dose per unit time.

Monitoring Schedule Per Endocrine Society Guidelines

The 2018 Endocrine Society guideline specifies hematocrit monitoring at 3 to 6 months after initiating TRT and then annually if stable. If hematocrit exceeds 54%, the guideline states: "Stop testosterone therapy until hematocrit decreases to a safe level; evaluate the patient for hypoxia and sleep apnea... Reinitiate therapy at a reduced dose."

Altitude, Exercise, and EPO: Non-Nutritional Context

Altitude and aerobic training affect hematocrit through EPO-mediated erythropoiesis. At elevations above 2,500 meters, EPO rises within 2 hours and erythropoiesis accelerates within 48 to 72 hours. After 2 to 4 weeks, hematocrit typically rises 3 to 7 percentage points. A study of 50 athletes completing a 4-week altitude training camp at 2,320 meters reported a mean hematocrit increase of 4.1% (from 43.6% to 47.7%), with full return to baseline within 3 weeks of returning to sea level.

Regular endurance training at sea level produces a plasma volume expansion that can lower hematocrit by 2 to 3% ("sports anemia"), even as total red cell mass increases slightly. This is a benign adaptation, not true anemia.

What Is the Optimal Hematocrit Range?

The question of "optimal" hematocrit separates into three clinical contexts: general health, cardiovascular risk, and performance.

General Health and Cardiovascular Risk

Observational data from the Cardiovascular Health Study (N=5,888) found a U-shaped association between hematocrit and cardiovascular mortality: risk increased below 36% and above 50% in both sexes. The nadir of risk in that dataset was 40 to 48% for men and 37 to 44% for women.

Polycythemia vera research has established that hematocrit above 45% in men with the JAK2 mutation is associated with a significantly higher rate of thrombotic events. The CYTO-PV trial (N=365) showed that maintaining hematocrit below 45% (versus tolerating up to 50%) reduced the composite of cardiovascular death and major thrombosis by 60% (4.4% vs. 10.9% annual rate, P<0.001). This threshold is now embedded in European LeukemiaNet guidelines.

Performance and Longevity Contexts

Endurance athletes and longevity-oriented clinicians frequently target hematocrit in the 42 to 48% range for men, as values in this window correspond to optimal oxygen-carrying capacity without a meaningful increase in blood viscosity. Values above 50% increase whole-blood viscosity non-linearly, raising peripheral resistance and the theoretical thrombosis risk even in healthy individuals.

TRT-Specific Target

For men on TRT, the practical operational target used by most hormone specialists is 40 to 50%, with a hard ceiling of 54% triggering protocol adjustment. Maintaining hematocrit between 42 to 50% on TRT represents adequate erythropoietic response to therapy without entering the range associated with venous thromboembolism risk observed in registry data.

Practical Nutrition Protocol to Manage Hematocrit

The following recommendations apply to patients whose hematocrit is either borderline low (35 to 39% in men, 33 to 36% in women) or borderline elevated (50 to 53%) from non-pharmacological causes.

For low hematocrit from nutritional deficiency:

• Confirm iron, ferritin, serum folate, and serum B12 before supplementing. Treating the wrong deficiency delays recovery.
• If iron-deficient: ferrous sulfate 325 mg (65 mg elemental iron) every other day on an empty stomach with 200 mg vitamin C. Every-other-day dosing was shown in a 2017 RCT (N=90) to produce equivalent or superior iron absorption to daily dosing, with fewer GI side effects, due to hepcidin cycling.
• If folate-deficient: 1 mg folic acid daily for 4 months, then reassess.
• If B12-deficient: 1,000 mcg cyanocobalamin or methylcobalamin orally daily (high-dose oral B12 bypasses intrinsic factor dependence) or monthly intramuscular injections.

For elevated hematocrit without TRT or polycythemia vera:

• Ensure adequate daily hydration (approximately 35 mL/kg body weight per day adjusted for activity and climate).
• Avoid iron supplementation in the absence of confirmed deficiency.
• Avoid high-altitude living or training until the elevated reading is investigated.
• Re-draw the test under controlled conditions (morning, rested, euhydrated) before acting on a single high result.

Key Drug Interactions Affecting Hematocrit

Several medications commonly prescribed in TRT and metabolic health contexts affect hematocrit directly:

• Testosterone (cypionate, enanthate, undecanoate): raises hematocrit via EPO stimulation; dose-dependent effect.
• Recombinant EPO (epoetin alfa, darbepoetin): used in renal anemia; can raise hematocrit above 55% if not monitored carefully. The FDA label for Epogen specifies a target hemoglobin of 10 to 12 g/dL (hematocrit ~30 to 36%) in CKD to avoid cardiovascular events.
• Metformin (500 to 2,000 mg/day): impairs B12 absorption after long-term use; can slowly lower hematocrit over years if B12 is not monitored. The ADA Standards of Care recommend periodic B12 assessment in all patients on long-term metformin.
• GLP-1 receptor agonists (semaglutide, tirzepatide): modest weight loss can reduce plasma volume concentration, producing a small decrease in hematocrit of 1 to 2% in obese patients losing significant body weight.
• ACE inhibitors: suppress erythropoiesis mildly by reducing angiotensin II-mediated EPO stimulation; a known but clinically minor effect.